My dabigatran article from Annals of Internal Medicine has been cited in Journal Watch. Huzzah!
“Within 12 weeks of marketing approval, dabigatran was found to be
responsible for more adverse events than nearly all other medications.
By David Green, MD, PhD”
Dabigatran: How Safe?
http://oncology-hematology.jwatch.org/cgi/content/full/2012/731/1